Table 2 Main investigational drugs in RRMM
Trial/NTC Id | Arms / Phase | N | New agent | Number of prior lines | PFS (months) | ORR (%) CBR (%) | Median duration (months) | TTNT (months) | OS (months) | All /(>G3) AEs (%) |
|---|---|---|---|---|---|---|---|---|---|---|
O-12-M1 [79] | Md Phase 1-2 | 81 | Melflufen IV, 15, 25, 40 or 55mg (40mg: maximum tolerated dose) | 4 (3-5) | 5.7 | 31 49 | 8.4 | NM | 20.7 | TP, 42 NP, 26 Infection, 8 |
NCT02899052 | Venetoclax + Kd Phase 2 | 42 | Venetoclax PO, 400 or 800mg | 2 (1-3) | 78 (100 % in t(11;14) | NP, 14 AH, 12 | ||||
NCT03314181 | Venetoclax + Dd Phase 1-2 | 24 | Venetoclax, PO, various doses | 3 (1-8) | 92 | NP, 13 AH, 8 | ||||
BOSTON [80] | Vd ± selinexor Phase 3 | 404 | Selinexor PO, 100mg oral, QW | 1-3 | 13.93 vs. 9.46 HR 0.70 | 76 vs. 62 | 20.3 vs. 12.9 | 16.1 vs. 10.8 | NR vs. 25 | TP, 39 vs. 17 Fatigue, 13 vs. 1 Nausea, 8 vs. 0 PNP (≥ G2), 21 vs. 34 |
PANORAMA 1 [18] | Vd ± panobinostat Phase 3 | 768 | Panobinostat PO, 20mg | 1-3 | 11.99 vs. 8.08 HR 0.63 | 61 vs. 54 | 13.1 vs. 10.9 | 40.3 vs. 35.8 | Diarrhea, 25 vs.8 Fatigue, 24 vs. 13 PN, 13 vs. 11 PNP, 18 vs. 15 | |
NCT02384083 | Filanesib + Pd, Phase 2 | 33 | Filanesib IV, various doses | 3 (2-6) | 7 | 65 | NM | NM | NM | NP, 60 |